Slow and steady wins the weight loss race with GLP-1s
Clinical Takeaway GLP-1 medications are started at low doses and increased gradually every week or two to let your body adjust and minimize nausea. Think of it like turning up the volume slowly instead of blasting your speakers. Your doctor titrates…
GLP-1 Digest: Latest Research and Clinical Updates May 06, 2
Clinical Takeaway GLP-1 receptor agonists have demonstrated substantial clinical efficacy across multiple indications, from weight management to inflammatory bowel disease, while simultaneously generating significant returns on research and development…
Clinical Evidence of Semaglutide in Alcohol Use Disorder
Semaglutide alcohol use disorder clinical evidence reveals promising reductions in alcohol consumption among severe AUD patients. This expands GLP-1 receptor agonists' role beyond metabolic effects. Understanding this evidence helps clinicians consider…
Effect of Glucagon-Like-Peptide-1 Receptor Agonists on Neuropsychiatric Outcomes
This meta-analysis examines GLP-1 receptor agonists neuropsychiatric effects across 82 studies. Evidence suggests potential benefits including Parkinson's disease risk reduction. However, the quality of evidence limits clinical recommendations beyond…
GLP-1 Digest: Latest Research and Clinical Updates April 25,
GLP-1 weight loss medicine has become a transformative option in metabolic care. This digest reviews clinical evidence for tirzepatide, semaglutide, and liraglutide. It highlights outcomes in weight management and cardiovascular protection.
Exploring the Endocannabinoid System in Mental Health Treatment Research
This article reviews recent endocannabinoid system mental health research focusing on its role in psychiatric disorders. Current studies explore how this system influences mental health treatment outcomes. Understanding these mechanisms may guide future…
Exploring GLP-1 Receptor Agonists for Neuroprotection
GLP-1 receptor agonists neuroprotection is an emerging area of research showing potential benefits beyond metabolic effects. These agents may reduce amyloid and tau protein accumulation linked to dementia. Current evidence supports further study of their…
GLP-1 Digest: Latest Research and Clinical Updates April 23,
The GLP-1 Digest April 23 Clinical Updates highlight transformative research on GLP-1 receptor agonists. This includes Medicare coverage changes for 2026 and pediatric applications. Tirzepatide’s cardiovascular outcomes are also reviewed in this digest.
GLP-1 Receptor Agonists and Colorectal Cancer Risk
GLP-1 receptor agonists colorectal cancer risk reduction is an emerging benefit supported by observational evidence. These agents may reduce colorectal cancer risk through improved insulin sensitivity and reduced inflammation. This adds to their known…
Clinical Insights on GLP-1 Receptor Agonists and Mental Health
This guide reviews the glp-1 receptor agonists mental health evidence, highlighting current research on their effects on major mental illnesses. While some mood improvements are noted, these medications are not primary psychiatric treatments.…